| Assessment Status | Rapid review complete |
| HTA ID | 22055 |
| Drug | Entrectinib |
| Brand | Rozlytrek® |
| Indication | As monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor and who have no satisfactory treatment options |
| Assessment Process | |
| Rapid review commissioned | 09/08/2022 |
| Rapid review completed | 29/09/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of entrectinib compared with the current standard of care, on the basis of the proposed price relative to currently available therapies |
The HSE has approved reimbursement following confidential price negotiations. October 2024
